Is Cyclopharm a good dividend stock?

Cyclopharm (ASX:CYC) pays an annual dividend of A$0.01 per share and currently has a dividend yield of 0.56%. Read our dividend analysis for CYC .

ASX:CYC

Cyclopharm (CYC) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CYC Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 10,000 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: 0.56%
Price Target: N/A

Stock Analysis

Get Cyclopharm alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Cyclopharm

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

CYC Stock News Headlines

January 11, 2023 | finance.yahoo.com

We're Interested To See How Cyclopharm (ASX:CYC) Uses Its Cash Hoard To Grow

January 11, 2023 | finance.yahoo.com

Further weakness as Cyclopharm (ASX:CYC) drops 13% this week, taking one-year losses to 59%

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

January 11, 2023 | finance.yahoo.com

Cyclopharm's (ASX:CYC) investors will be pleased with their favorable 42% return over the last five years

See More Headlines

Receive CYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclopharm and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Medical Devices
Sub-Industry: N/A
Current Symbol: ASX:CYC
CUSIP: N/A
CIK: N/A
Web: www.cyclopharm.com.au
Phone: 61 2 9541 0411
Fax: N/A
Employees: 87
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.05)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,700,000.00
Net Margins: -17.32%
Pretax Margin: N/A
Return on Equity: -13.67%
Return on Assets: -12.08%

Debt

Debt-to-Equity Ratio: 13.10
Current Ratio: 3.48
Quick Ratio: 4.68

Sales & Book Value

Annual Sales: $27.14 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 8.40
Book Value: A$0.34 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 94,100,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.80

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. James S. McBrayer AIM (Age 59)
BSPharm, F.A.C.I.D., FAICD, GDM, CEO, MD, Company Secretary & Director
Comp: $624.04k
Mr. Mathew Farag
Chief Operating Officer
Mr. Graham N. Phillips
Finance Manager
Ms. Sally-Ann Cornelius
Head of Sales
Ms. Niamh McAree
Head of Quality and Regulatory
Mr. Chris Quinn
Head of Service
Ms. Sui Ling Cheah (Age 54)
Financial Controller
Comp: $63.73k
Mr. Lynn McLauchlin
General Manager of Canada
Mr. Gary T. Somerville
Quality & Regulatory Manager

Key Competitors

View All Competitors

Insiders

CYC Stock Analysis - Frequently Asked Questions

Is Cyclopharm a good dividend stock?: Cyclopharm (ASX:CYC) pays an annual dividend of A$0.01 per share and currently has a dividend yield of 0.56%.
Read our dividend analysis for CYC.

This page (ASX:CYC) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cyclopharm (CYC) Stock Price, News & Analysis

About Cyclopharm

CYC Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

CYC Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info